Literature DB >> 30343423

Who Will Win: Induced Pluripotent Stem Cells Versus Embryonic Stem Cells for β Cell Replacement and Diabetes Disease Modeling?

Elena F Jacobson1, Emmanuel S Tzanakakis2,3.   

Abstract

PURPOSE OF REVIEW: Ever since the reprogramming of human fibroblasts to induced pluripotent stem cells (hiPSCs), scientists have been trying to determine if hiPSCs can give rise to progeny akin to native terminally differentiated cells as human embryonic stem cells (hESCs) do. Many different somatic cell types have been successfully reprogrammed via a variety of methods. In this review, we will discuss recent studies comparing hiPSCs and hESCs and their ability to differentiate to desired cell types as well as explore diabetes disease models. RECENT
FINDINGS: Both somatic cell origin and the reprogramming method are important to the epigenetic state of the hiPSCs; however, genetic background contributes the most to differences seen between hiPSCs and hESCs. Based on our review of the relevant literature, hiPSCs display differences compared to hESCs, including a higher propensity for specification toward particular cell types based on memory retained from the somatic cell of origin. Moreover, hiPSCs provide a unique opportunity for creating diabetes disease models.

Entities:  

Keywords:  Diabetes; Differentiation; Disease models; Human pluripotent stem cells; Reprogramming

Mesh:

Year:  2018        PMID: 30343423     DOI: 10.1007/s11892-018-1109-y

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  34 in total

1.  Copy number variation and selection during reprogramming to pluripotency.

Authors:  Samer M Hussein; Nizar N Batada; Sanna Vuoristo; Reagan W Ching; Reija Autio; Elisa Närvä; Siemon Ng; Michel Sourour; Riikka Hämäläinen; Cia Olsson; Karolina Lundin; Milla Mikkola; Ras Trokovic; Michael Peitz; Oliver Brüstle; David P Bazett-Jones; Kari Alitalo; Riitta Lahesmaa; Andras Nagy; Timo Otonkoski
Journal:  Nature       Date:  2011-03-03       Impact factor: 49.962

2.  Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells.

Authors:  Alireza Rezania; Jennifer E Bruin; Payal Arora; Allison Rubin; Irina Batushansky; Ali Asadi; Shannon O'Dwyer; Nina Quiskamp; Majid Mojibian; Tobias Albrecht; Yu Hsuan Carol Yang; James D Johnson; Timothy J Kieffer
Journal:  Nat Biotechnol       Date:  2014-09-11       Impact factor: 54.908

3.  Epigenetic Variation between Human Induced Pluripotent Stem Cell Lines Is an Indicator of Differentiation Capacity.

Authors:  Masatoshi Nishizawa; Kazuhisa Chonabayashi; Masaki Nomura; Azusa Tanaka; Masahiro Nakamura; Azusa Inagaki; Misato Nishikawa; Ikue Takei; Akiko Oishi; Koji Tanabe; Mari Ohnuki; Hidaka Yokota; Michiyo Koyanagi-Aoi; Keisuke Okita; Akira Watanabe; Akifumi Takaori-Kondo; Shinya Yamanaka; Yoshinori Yoshida
Journal:  Cell Stem Cell       Date:  2016-07-28       Impact factor: 24.633

4.  Generation of Human-Induced Pluripotent Stem Cells from Wolfram Syndrome Type 2 Patients Bearing the c.103 + 1G>A CISD2 Mutation for Disease Modeling.

Authors:  Alberto La Spada; Aikaterini Ntai; Stefano Genovese; Maurizio Rondinelli; Pasquale De Blasio; Ida Biunno
Journal:  Stem Cells Dev       Date:  2018-01-22       Impact factor: 3.272

5.  Embryonic stem cell lines derived from human blastocysts.

Authors:  J A Thomson; J Itskovitz-Eldor; S S Shapiro; M A Waknitz; J J Swiergiel; V S Marshall; J M Jones
Journal:  Science       Date:  1998-11-06       Impact factor: 47.728

6.  Derivation of human induced pluripotent stem cells from patients with maturity onset diabetes of the young.

Authors:  Adrian K K Teo; Rebecca Windmueller; Bente B Johansson; Ercument Dirice; Pal R Njolstad; Erling Tjora; Helge Raeder; Rohit N Kulkarni
Journal:  J Biol Chem       Date:  2013-01-10       Impact factor: 5.157

7.  Development of a rapid screen for the endodermal differentiation potential of human pluripotent stem cell lines.

Authors:  Richard Siller; Elena Naumovska; Santosh Mathapati; Max Lycke; Sebastian Greenhough; Gareth J Sullivan
Journal:  Sci Rep       Date:  2016-11-22       Impact factor: 4.379

Review 8.  Is islet transplantation a realistic approach to curing diabetes?

Authors:  Sang-Man Jin; Kwang-Won Kim
Journal:  Korean J Intern Med       Date:  2017-01-01       Impact factor: 2.884

9.  Insulin-producing cells derived from 'induced pluripotent stem cells' of patients with fulminant type 1 diabetes: Vulnerability to cytokine insults and increased expression of apoptosis-related genes.

Authors:  Yoshiya Hosokawa; Taro Toyoda; Kenji Fukui; Megu Yamaguchi Baden; Michinori Funato; Yasushi Kondo; Tomomi Sudo; Hiromi Iwahashi; Marina Kishida; Chihiro Okada; Akira Watanabe; Isao Asaka; Kenji Osafune; Akihisa Imagawa; Iichiro Shimomura
Journal:  J Diabetes Investig       Date:  2017-08-10       Impact factor: 4.232

10.  Genes Associated with Pancreas Development and Function Maintain Open Chromatin in iPSCs Generated from Human Pancreatic Beta Cells.

Authors:  Matthias Thurner; Liraz Shenhav; Agata Wesolowska-Andersen; Amanda J Bennett; Amy Barrett; Anna L Gloyn; Mark I McCarthy; Nicola L Beer; Shimon Efrat
Journal:  Stem Cell Reports       Date:  2017-11-01       Impact factor: 7.765

View more
  3 in total

Review 1.  Embryonic Stem Cells in Clinical Trials: Current Overview of Developments and Challenges.

Authors:  Ali Golchin; Alexia Chatziparasidou; Parviz Ranjbarvan; Zahra Niknam; Abdolreza Ardeshirylajimi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Therapeutic Potential of Wharton's Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges.

Authors:  Mohamed M Kamal; Dina H Kassem
Journal:  Front Cell Dev Biol       Date:  2020-01-29

Review 3.  Modeling Maturity Onset Diabetes of the Young in Pluripotent Stem Cells: Challenges and Achievements.

Authors:  Carmel Braverman-Gross; Nissim Benvenisty
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-22       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.